A double blind, placebo controlled study of a platelet activating factor antagonist in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 25, Issue 8, 1998, Pages 1502-1507

  Hilliquin, Pascal ^a,b   Chermat Izard, Valérie ^a,d   Menkes, Charles Jöel ^a,c,e  

^a Institut de Rhumatologie Hopital Cochin   (France)

^b Hôpital Cochin

^c Univ René Descartes

^d Institut Henri Beaufour   (France)

^e NONE   (France)

Author keywords

Platelet activating factor; Platelet activating factor antagonists; Rheumatoid arthritis

Indexed keywords

6 (2 CHLOROPHENYL) 4,7,8,10 TETRAHYDRO 9 (4 METHOXYPHENYLCARBAMOYL) 1 METHYLPYRIDO[4',3':4,5]THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE; THROMBOCYTE ACTIVATING FACTOR RECEPTOR AFFECTING AGENT;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HUMAN; INFLAMMATION; MORNING STIFFNESS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHEUMATOID ARTHRITIS; STROKE; SYMPTOMATOLOGY; TREATMENT FAILURE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 0031927508     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Pinckard RN, Ludwig JC, McManus LM. Platelet-activating factor. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation. New York: Raven Press; 1988:139-67.
2. Benveniste J. The history and some prospects of paf-acether (PAF or AGEDC). In: Handley DA, Saunders RN, Houlihan WJ, Tomesch JC, editors. Platelet-activating factor in endotoxin and immune diseases. New York: Marcel Dekker; 1989:3-14.
3. Jouvin-Marche E, Ninio E, Beaurain G, Tencé M, Niaudet P, Benveniste J. Biosynthesis of paf-acether (platelet-activating factor). VII. Precursors of paf-acether and acetyl-transferase activity in human leukocytes. J Immunol 1984;133:892-8.
4. Camussi G, Bussolino F, Salvidio G, Baglioni C. Tumor necrosis factor/cachectin stimulates rat peritoneal macrophages and human endothelial cells to synthesize and release platelet activating factor. J Exp Med 1987;166:1390-6.
5. Camussi G, Bussolino F, Tetta C, Piacibello W, Aglietta M. Biosynthesis and release of platelet-activating factor from human monocytes. Int Arch Allergy Appl Immunol 1983;70:245-51.
6. Mencia-Huerta JM, Benveniste J. Platelet-activating factor (paf-acether) and macrophages. II. Phagocytosis-associated release of PAF-acether from rat peritoneal macrophages. Cell Immunol 1981;57:281-92.
7. Le Gouvello S, Vivier E, Debré P, Thomas Y, Colard O. CD2 triggering stimulates the formation of platelet-activating factor-acether from alkyl-arachidonoyl-glycerophosphocholine in a human CD4+ T lymphocyte clone. J Immunol 1992;149:1289-93.
8. Hilliquin P, Menkès CJ, Laoussadi S, Benveniste J, Arnoux B. Presence of paf-acether in rheumatic diseases. Ann Rheum Dis 1992;51:29-31.
9. Hilliquin P, Houbaba H, Aissa J, Benveniste J, Menkès CJ. Correlations between paf-acether and tumor necrosis factor in rheumatoid arthritis. Influence of parenteral corticosteroids. Scand J Rheumatol 1995;24:169-73.
10. Dulioust A, Hilliquin P, Menkès CJ, Benveniste J, Arnoux B. Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases. Scand J Rheumatol 1992;21:61-4.
11. Pettipher ER, Higgs GA, Henderson B. PAF-acether in chronic arthritis. Agents Actions 1987;21:98-103.
12. Fernandes AJ, Calvo IF, de Falco V, da Rocha FA, Sirois P, Jancar S. Mechanisms of thrombocytopenia in the acute phase of antigen-induced arthritis in rabbits. Prostaglandins 1991;42:493-500.
13. Zarco P, Maestre C, Herrero-Beaumont G, et al. Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits. Clin Exp Immunol 1992;88:318-23.
14. Hilliquin P, Natour J, Guinot P, Amsellem R, Menkès CJ, Arnoux B. Therapeutic effects of a paf-acether antagonist BN 50730 in carrageenan-induced arthritis in rabbits. Ann Rheum Dis 1995;54:140-3.
15. Hilliquin P, Guinot P, Chermat-Izard V, Puéchal X, Menkès CJ. Treatment of rheumatoid arthritis with platelet-activating factor antagonist BN 50730. J Rheumatol 1995;22:1651-4.
16. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Shalit M, Von Allmen C, Atkins PC, Zweiman B. Platelet-activating factor increases expression of complement receptors on human neutrophils. J Leuk Biol 1988;44:212-7.
18. Vercelotti GM, Yin HO, Gustafson KS, Nelson RD, Jacob HS. Platelet-activating factor primes neutrophil responses to agonist: role in promoting neutrophil-mediated endothelial damage. Blood 1988;71:1100-7.
19. Hilliquin P, Dulioust A, Gregoir C, Arnoux A, Menkès CJ. Production of paf-acether by synovial fluid neutrophils in rheumatoid arthritis. Inflamm Res (Agents Actions) 1995;44:313-6.
20. Dulioust A, Duprez V, Pitton C, et al. Immunoregulatory functions of paf-acether. III. Down-regulation of CD4+ T cells high-affinity IL-2 receptor expression. J Immunol 1990;144:3123-9.
21. Behrens TW, Goodwin JS. Control of human T cell proliferation by platelet-activating factor. Int J Immunopharmacol 1990;12:175-84.
22. Calabresse C, Nguer MC, Pellegrini O, Benveniste J, Richard Y, Thomas Y. Induction of high-affinity paf receptor expression during T cell activation. Eur J Immunol 1992;22:1349-55.
23. Mangino MJ, Murphy MK, Weiss A, Anderson CB. Characterization of platelet-activating factor receptors on canine T lymphocytes. J Immunol 1993;151:5310-8.
24. Tordai A, Franklin RA, Johnson C, Mazer BD, Clay KL, Gelfand EW. Autocrine stimulation of B lymphocytes by a platelet-activating factor receptor agonist, 1-palmitoyl-2-acetyl-sn-glycero-3-phosphocholine. J Immunol 1994;152:566-73.
25. Mandi Y, Farkas G, Koltai M, Beladi I, Mencia-Huerta JM, Braquet P. The effect of the platelet-activating factor antagonist, BN 52021, on human natural killer cell-mediated cytotoxicity. Immunol 1989;67:370-4.
26. Miguelez R, Palacios I, Navarro F, et al. Abrogation of mice collagen-induced arthritis by treatment with two paf receptor antagonists [abstract]. Arthritis Rheum 1995; 38 Suppl:S372.
27. Gutierrez S, Palacios I, Egido J, et al. IL-1 beta and IL-6 stimulate the production of platelet-activating factor by cultured rabbit synovial cells. Clin Exp Immunol 1995;99:364-8.
28. Maestre C, Zarco P, Gomez-Guerrero C, et al. Cooperation between tumor necrosis factor and platelet-activating factor in the inflammatory response. J Lipid Mediat 1990; 2 Suppl:151-9.
29. Poubelle PE, Gingras D, Demers C, et al. Platelet activating factor (PAF-acether) enhances the concomitant production of tumor necrosis factor-alpha and interleukin-1 by subsets of human monocytes. Immunol 1991;72:181-7.
30. Valone FH, Ruis NM. Stimulation of tumor necrosis factor release by cytotoxic analogues of platelet-activating factor. Immunol 1992;76:24-9.
31. Hunyadi J, Kenderessy AS, Duda E, Braquet P, Dobozy A. Platelet-activating factor antagonists (BN 52021 and BN 50730) inhibit tumor necrosis factor-alfa-mediated cytotoxicity on murine L929 tumor cells. Mol Immunol 1993;30:517-9.
32. Benfield TL, Lundgren JD. PAF receptor antagonists in the treatment of asthma. Exp Opin Invest Drugs 1994;3:733-42.
33. Dhainault JF, Tenaillon A, Le Tulzo Y, et al. Platelet activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994;22;1720-8.
34. Spinnewyn B, Blavet N, Pirotzky E, Braquet P. The platelet-activating factor antagonist, BN 50730, protects against the development of experimental autoimmune encephalomyelitis. J Lipid Med Cell Sign 1994;10:135-7.
35. Doly M, Cluzel J, Millerin M, Bonhomme B, Braquet P. Prevention of chloroquine-induced electroretinographic damage by a new platelet-activating factor antagonist, BN 50730. Ophthalmol Res 1993;25:314-8.